In cancer biology, eEF2 modification plays a crucial role, as demonstrated by studies using diphthamide-deficient MCF7 breast cancer cells, where the loss of diphthamide blocked ADP-ribosylation, conferring resistance to Pseudomonas exotoxin A (PE) and diphtheria toxin (DT) [57]. The gene discussed is EEF2; the disease is breast cancer.